North America Botulinum Toxin Market Size, Share & Industry Trends Analysis Report By Product, By Application (Therapeutic and Aesthetic), By End User (Hospitals, Dermatology Clinics and Spas & Cosmetic Centers, By Country and Growth Forecast, 2022 - 2028

The North America Botulinum Toxin Market would witness market growth of 10.3% CAGR during the forecast period (2022-2028).

Glabellar lines, crow's feet, or forehead lines are among the age-related diseases that are treated with botulinum toxin. As a result, adults over 40 are more susceptible to these aging symptoms. As a result, among those between the ages of 40 and 55, botulinum toxin procedures are becoming more and more popular, supporting business growth.

Botulinum toxin administered intramuscularly causes muscle paralysis at the neuromuscular junction by inhibiting the release of acetylcholine by presynaptic motor neurons. The autonomic ganglia, neuromuscular junction, postganglionic parasympathetic nerve terminals, and postganglionic sympathetic nerve ends that release acetylcholine are the four places in the body where botulinum toxins activate. The cholinergic neurons’ presynaptic surface has high-affinity receptors that the toxin's heavy (H) chain preferentially and irreversibly attach to. The toxin-receptor complex is then taken up into the cell through endocytosis. In order for the poison to escape into the cytoplasm, the disulfide connection holding the two chains together is broken.

The utilization of botulinum toxin is increasing in the region in recent years. Not all headaches are bad with migraine. Compared to other headache illnesses, it is a disabling neurological disease with unique symptoms and a unique strategy for therapy. According to the American Migraine Foundation, approximately 39 million Americans suffer from migraines, however, the true figure is likely greater because many sufferers do not receive a proper diagnosis or treatment.

The US market dominated the North America Botulinum Toxin Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $2,774.1 Million by 2028.The Canada market is poised to grow at a CAGR of 12.8% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 11.8% during (2022 - 2028).

Based on Product, the market is segmented into Type A and Type B. Based on Application, the market is segmented into Therapeutic and Aesthetic. Based on End User, the market is segmented into Hospitals, Dermatology Clinics and Spas & Cosmetic Centers. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

Free Valuable Insights: The Global Botulinum Toxin Market is Estimated to reach $10.5 Billion by 2028, at a CAGR of 10.8%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Evolus, Inc. (Alphaeon Corporation), Merz Pharma GmbH & Co. KGaA, AbbVie, Inc., Ipsen Pharma, Galderma S.A., USWM, LLC, and Metabiologics, Inc. (Object Pharma).

Scope of the Study

Market Segments Covered in the Report:

By Product

• Type A
• Type B

By Application

• Therapeutic
• Aesthetic

By End User

• Hospitals
• Dermatology Clinics
• Spas & Cosmetic Centers

By Country

• US
• Canada
• Mexico
• Rest of North America

Key Market Players

List of Companies Profiled in the Report:

• Evolus, Inc. (Alphaeon Corporation)
• Merz Pharma GmbH & Co. KGaA
• AbbVie, Inc.
• Ipsen Pharma
• Galderma S.A.
• USWM, LLC
• Metabiologics, Inc. (Object Pharma)

Unique Offerings from KBV Research

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

Related Reports:

Global Botulinum Toxin Market Report 2022-2028

Europe Botulinum Toxin Market Report 2022-2028

Asia Pacific Botulinum Toxin Market Report 2022-2028

LAMEA Botulinum Toxin Market Report 2022-2028